UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.
Minchell, Laura J
Roberts, Stephen A
Hadfield, Kristen D
Blackhall, Fiona H
Mullamitha, Saifee A
Valle, Juan W
Saunders, Mark P
Newman, William G
AffiliationDepartment of Medical Genetics, St Mary's Hospital, Manchester, UK.
MetadataShow full item record
AbstractAIMS: Variants in UGT1A1 have previously been associated with toxicity from irinotecan chemotherapy. We conducted a pragmatic prospective cohort study to establish the relevance of UGT1A1 variants in the prediction of severe diarrhea and neutropenia in patients with colorectal cancer receiving irinotecan in a routine clinical setting. MATERIALS & METHODS: Genotyping of UGT1A1*28 and c.-3156G>A was undertaken in an unselected, prospective cohort of 96 individuals treated with irinotecan at a single major UK oncology centre. Data on cytotoxic drugs received, and toxicity for all irinotecan treatment cycles were collected from case notes. Over 95% (92/96) of patients received an intermediate dose of irinotecan (180 mg/m(2), twice weekly). Irinotecan was given in combination with other cytotoxic drugs in 93/96 subjects and Grade 3 or 4 toxicity occurred in 23% of subjects. RESULTS: No association was found between UGT1A1*28 or c.-3156G>A and neutropenia. However, individuals carrying two copies of UGT1A1*28 (p = 0.04; OR: 14; 95% CI: 1.1-185) or c.-3156G>A (p = 0.03) had a significantly increased risk of diarrhea over all cycles. CONCLUSION: Our findings indicate that UGT1A1 genotyping is not a good predictor of hematological toxicity in patients treated with intermediate irinotecan doses. However, it may be useful in the identification of patients at risk of severe diarrhea.
CitationUGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. 2009, 10 (5):733-9 Pharmacogenomics
- Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
- Authors: Massacesi C, Terrazzino S, Marcucci F, Rocchi MB, Lippe P, Bisonni R, Lombardo M, Pilone A, Mattioli R, Leon A
- Issue date: 2006 Mar 1
- UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.
- Authors: Marcuello E, Altés A, Menoyo A, Del Rio E, Gómez-Pardo M, Baiget M
- Issue date: 2004 Aug 16
- Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
- Authors: Fakih MG, Ross ME, Starostik P
- Issue date: 2007 Jul
- Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
- Authors: Liu D, Li J, Gao J, Li Y, Yang R, Shen L
- Issue date: 2017 Jun 20
- A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients.
- Authors: Li J, Yu Q, Fu S, Xu M, Zhang T, Xie C, Feng J, Chen J, Zang A, Cai Y, Fu Q, Liu S, Zhang M, Hong Q, Huang L, Yuan X
- Issue date: 2016 Jul